Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cue Biopharma, Inc.

NASDAQ: CUE · Life Sciences · 5 alerts · CIK 1645460

Share price
$14.10Close, Nov 16
Market cap
$102M
Shares outstanding
7.26MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cue Biopharma, Inc. filings on SEC EDGAR ↗

8:01 AM ET 8-K
Clinical Trial Data

Cue Biopharma Clinical Trial Data

Cue Biopharma announced positive topline results from a Phase 2 clinical trial of CUE-221 in patients with moderate to severe Chronic Spontaneous Urticaria (CSU). The study met its primary endpoint of complete resolution of hives (HSS7=0) at all dose levels with high statistical significance, demonstrating superiority over placebo and showing a favorable safety profile. The company plans to advance the candidate into a Phase 2b/3 registration-enabling study based on these results.

Counterparty
Genesis Life Sciences
Term
36 weeks

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.